Class of Stock [Axis] Common Stock, $0.001 par value per share 8.625% Senior Notes due 2026 Product and Service [Axis] Product sales net [Member] Other revenues [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total harrow health inc stockholders equity [Member] Noncontrolling Interest [Member] Award Type [Axis] Warrant [Member] Equity Option [Member] Series [Axis] Eton Pharmaceuticals, Inc. [Member] Statistical Measurement [Axis] Maximum [Member] Melt Pharmaceuticals, Inc. [Member] Surface Pharmaceuticals Inc [Member] Commissions [Member] License [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Management Services Agreement [Member] Mel Loan Agreement [Member] Title of Individual [Axis] Chief Executive Officer [Member] Minimum [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Licenses [Member] Trademarks [Member] Customer Relationships [Member] Trade Names [Member] Non-Competition Clause [Member] State Pharmacy Licenses [Member] Long-term Debt, Type [Axis] Investor [Member] Term Loan and Security Agreement [Member] SWK Funding LLC [Member] Variable Rate [Axis] London Interbank Offered Rate (LIBOR) [Member] Base Rate [Member] Regulatory Asset [Axis] Deferred Gain (Loss) on Early Extinguishment of Debt [Member] Business Loan Agreement [Member] Geographical [Axis] San Diego [Member] Ledgewood [Member] Lease Contractual Term [Axis] Additional Square Footage of Lease [Member] Nashville [Member] NEW JERSEY Property Subject to or Available for Operating Lease [Axis] One Thousand Aviara Lease [Member] Income Statement Location [Axis] Selling, General and Administrative Expenses [Member] Series B Cumulative Preferred Stock Redeemed [Member] Options Held [Member] Mark L. Baum [Member] Restricted Stock Units (RSUs) [Member] Andrew R. Boll [Member] Director [Member] Plan Name [Axis] 2017 Incentive Stock and Awards Plan [Member] Stock Option Plan [Member] Stock Option Plan [Member] Employees and Consultant [Member] Options Granted to Employees [Member] Exercise Price Range [Axis] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Employees [Member] Vesting [Axis] Share-based Payment Arrangement, Tranche One [Member] Share-based Payment Arrangement, Tranche Two [Member] Share-based Payment Arrangement, Tranche Three [Member] Share Based Compensation Award Tranche Four [Member] Performance Stock Units P S U [Member] Unvested R S U [Member] Class of Warrant or Right [Axis] Related Party [Axis] Lender Warrants [Member] Subsidiary Stock Option Plan [Member] Selling, General and Administrative [Member] Employees Research and Development [Member] Consultants Selling General and Administrative [Member] Subsegments [Axis] Subsequent Event [Member] Richard L. Lindstrom, M.D [Member] Klarity License Agreement [Member] Scenario [Axis] Initial Payment [Member] License Agreement [Member] Second Payment [Member] Final Payment [Member] Injectable Asset Purchase Agreement [Member] Sales and Marketing Agreements [Member] Asset Purchase License And Related Agreements [Member] Mayfield Pharmaceuticals [Member] Asset Purchase Agreement [Member] Stowe License Agreement [Member] Sintetica Agreement [Member] Due Within 30 Days [Member] Wakamoto Agreement [Member] Consolidation Items [Axis] Operating Segments [Member] Segments [Axis] ImprimisRx [Member] Pharmaceutical Drug Development [Member] Corporate, Non-Segment [Member] Research and Development Expense [Member] Asset Sales And Impairments Net [Member] Concentration Risk Type [Axis] Product Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Two Product Concentration Risk [Member] Supplier Concentration Risk [Member] Cost of Goods and Service, Product and Service Benchmark [Member] Supplier [Axis] Three Main Suppliers [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents, including restricted cash of $200 Investment in Eton Pharmaceuticals Note receivable - Melt Pharmaceuticals Accounts receivable, net Inventories Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Operating lease right-of-use assets Intangible assets, net Investment in Surface Ophthalmics Investment in Melt Pharmaceuticals Goodwill TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable and accrued expenses Accrued payroll and related liabilities Deferred revenue and customer deposits Current portion of paycheck protection program loan payable Current portion of loan payable, net of unamortized debt discount Current portion of operating lease liabilities Current portion of finance lease obligations Total current liabilities Operating lease liabilities, net of current portion Finance lease obligations Accrued expenses, net of current portion Paycheck protection program loan payable, net of current portion Loan payable, net of current portion and unamortized debt discount TOTAL LIABILITIES COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY Common stock, $0.001 par value, 50,000,000 shares authorized, 26,902,763 and 25,749,875 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively Additional paid-in capital Accumulated deficit TOTAL HARROW HEALTH STOCKHOLDERS’ EQUITY Noncontrolling interests TOTAL EQUITY TOTAL LIABILITIES AND EQUITY Restricted cash Common stock, par value Common stock, sharess authorized Common stock, shares issued Common stock, shares outstanding Revenues: Total revenues Cost of sales Gross profit Operating expenses: Selling, general and administrative Research and development Impairment of intangible assets Total operating expenses (Loss) income from operations Other (expense) income: Interest expense, net Equity in losses of unconsolidated entities Investment (loss) gain from Eton Pharmaceuticals, net Loss from early extinguishment of loan Gain on forgiveness of PPP loan Other (expense) income, net Total other (expense) income, net Total net (loss) income including noncontrolling interests Net loss attributable to noncontrolling interest Net (loss) income attributable to Harrow Health, Inc. Preferred dividends and accretion of preferred stock issuance costs Net (loss) income attributable to common stockholders Basic net (loss) income per share of common stock Diluted net (loss) income per share of common stock Weighted average number of shares of common stock outstanding, basic Weighted average number of shares of common stock outstanding, diluted Beginning balance, value Balance,shares Exercise of employee stock-based options Exercise of employee stock-based options, shares Exercise of warrants Exercise of warrants, shares Issuance of common stock related to vesting of RSUs Issuance of common stock related to vesting of RSUs, shares Shares withheld related to net share settlement of equity awards  Shares withheld related to net share settlement of equity awards Issuance of preferred shares, net of discount and issuance costs Issuance of preferred shares, net of discount and issuance costs, shares Redemption of preferred shares Redemption of preferred shares, shares Payment of preferred dividends Stock-based payment for services provided Stock-based payment for services provided, shares Vesting of RSUs Vesting of RSUs, shares Stock-based compensation expense Net loss Ending balance, value Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss (including noncontrolling interests) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization of property, plant and equipment Amortization of intangible assets Amortization of operating lease right-of-use assets Provision for bad debt expense Amortization of debt issuance costs and discount Gain on forgiveness of PPP loan Investment loss from Eton, net Equity in losses of unconsolidated entities Interest income paid-in-kind from note receivable Loss on sale and disposal of assets Interest paid-in-kind on loan payable Impairment of long-lived assets Loss on early extinguishment of loan Stock-based payment of consulting services Stock-based compensation Changes in assets and liabilities: Accounts receivable Inventories Prepaid expenses and other current assets Accounts payable and accrued expenses Accrued payroll and related liabilities Deferred revenue and customer deposits NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Net proceeds on sale investments Issuance of note receivable, Melt Pharmaceuticals Investment in patent and trademark assets Purchases of property, plant and equipment NET CASH USED IN INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Payments on finance lease obligations Net proceeds from 8.625% notes payable, net of costs Principal and exit fee payments on SWK loan Net proceeds from PPP loan payable Proceeds from SWK debt, net of costs Payment of taxes upon vesting of RSUs Proceeds from exercise of stock options Sale of preferred stock, net of discount and issuance costs Repayment of preferred stock Payment of preferred stock dividends NET CASH PROVIDED BY FINANCING ACTIVITIES NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash and cash equivalents Restricted cash CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for income taxes Cash paid for interest SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Right-of-use asset obtained in exchange for lease obligation Net reduction in right-of-use assets and lease obligations due to modifications Issuance of common stock upon vesting of RSUs Melt accounts receivable transferred to note receivable Accounting Policies [Abstract] DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue from Contract with Customer [Abstract] REVENUES Investments, Debt and Equity Securities [Abstract] INVESTMENT IN, AND NOTE RECEIVABLE FROM MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS Investment In Surface Ophthalmics Inc. - Related Party Transactions INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS Restricted Cash RESTRICTED CASH Inventory Disclosure [Abstract] INVENTORIES Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] PREPAID EXPENSES AND OTHER CURRENT ASSETS Property, Plant and Equipment [Abstract] PROPERTY, PLANT AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS AND GOODWILL Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Debt Disclosure [Abstract] DEBT Leases LEASES Equity [Abstract] STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Segment Reporting [Abstract] SEGMENT INFORMATION AND CONCENTRATIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Risks, Uncertainties and Liquidity Segments Noncontrolling Interests Basic and Diluted Net Income (Loss) per Common Share Investment in Eton Pharmaceuticals, Inc. Investment in Melt Pharmaceuticals, Inc. – Related Party Investment in Surface Ophthalmics, Inc. – Related Party Impairment of Equity Method Investments and Note Receivable Research and Development Recently Adopted Accounting Pronouncements Reclassifications SCHEDULE OF BASIC AND DILUTED EARNINGS PER COMMON SHARE SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES SCHEDULE OF DILUTED NET INCOME LOSS PER SHARES SCHEDULE OF DISAGGREGATED REVENUE SUMMARY OF CONDENSED INCOME STATEMENT SUMMARY OF CONDENSED BALANCE SHEET SUMMARY OF CONDENSED INCOME STATEMENT SCHEDULE OF INVENTORIES SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT SCHEDULE OF INTANGIBLE ASSETS SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES SUMMARY OF FUTURE MINIMUM PAYMENTS SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES SCHEDULE OF FUTURE LEASE PAYMENTS UNDER FINANCE LEASE SCHEDULE OF STOCK OPTION PLAN ACTIVITY SCHEDULE OF FAIR VALUE ASSUMPTIONS SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION Consolidation basis, description Numerator – net (loss) income attributable to Harrow Health, Inc. common stockholders Denominator - weighted average number of shares outstanding, basic Net (loss) income per share, basic Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Dilutive common equivalent shares Numerator – net (loss) income attributable to Harrow Health, Inc. Denominator – weighted average number of shares outstanding, basic Number of shares used for diluted earnings per share computation Net (loss) income per share, diluted Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Unvested restricted stock units Vested restricted stock units Sale of stock. shares issued Shares issued, price per share Proceeds from sale stock Payments for commissions Realized loss on investments Number of shares owned Equity Method Investment, Ownership Percentage Shares price Unrealized Gain (Loss) on Investments Investment owned, at fair value Due from related parties Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenues, net Loss from operations Net loss Current assets Non-current assets Total assets Total liabilities Total stockholders’ equity Total liabilities and stockholders’ equity Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Administrative fees expense Melt accounts receivable transferred to note receivable Debt Instrument, Face Amount Debt Instrument, Interest Rate Debt Instrument, Interest RatE Effective Rate Investment Owned, Balance, Shares Raw materials Work in progress Finished goods Total inventories Prepaid insurance Due from Melt Pharmaceuticals Other prepaid expenses Deposits and other current assets Total prepaid expenses and other current assets Computer software and hardware Furniture and equipment Lab and pharmacy equipment Leasehold improvements  Property, plant and equipment, gross Accumulated depreciation and amortization Property, plant and equipment, net  Depreciation and amortization Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Amortization periods (in years) Cost Accumulated amortization Impairment Net carrying value Amortization periods description Amortization of intangible assets Remainder of 2021 2022 2023 2024 2025 Thereafter Intangible assets Accounts payable Other accrued expenses Accrued litigation settlement (see Note 15) Accrued interest Accrued exit fee for loan payable Total accounts payable and accrued expenses Less: Current portion Non-current total accrued expenses Remainder of 2021 2022 2023 2024 2025 2026 Total minimum payments Less: amount representing interest payments Notes payable, gross Less: unamortized discount, net of premium Notes payable, net of unamortized discount Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Debt principal amount Additional notes issued Share price Proceeds from issuance of debt Debt issuance costs and discounts Interest expense, debt Debt issuance costs Premium on issuance of debt Debt instrument, interest rate Debt instrument, redemption, description Interest Expense, debt Debt instrument interest rate Debt instrument interest rate description Debt instrument, additional principal amount Interest paid-in-kind Debt issuance expenses Extinguishment of debt [custom:GainLossOnForgivenessOfDebt] Schedule Of Future Lease Payments Under Operating Leases Remainder of 2021 2022 2023 2024 2025 Thereafter Total minimum lease payments Less: amount representing interest payments Total operating lease liabilities Less: current portion, operating lease liabilities Schedule Of Future Lease Payments Under Finance Lease Remainder of 2021 2022 2023 2024 Total minimum lease payments Less: amount representing interest payments Present value of future minimum lease payments Less: current portion, finance lease obligation Finance lease obligation, net of current portion Operating lease space Operating lease expires date Lease term description Weighted average incremental borrowing rate, operating lease Weighted average remaining lease term Operating lease liabilities Operating lease expense Weighted average incremental borrowing rate, financing lease Weighted average remaining lease term, finance lease Operating leases, income statement, depreciation expense on property subject to or held-for-lease Finance lease, interest expense Number of shares, Outstanding, Beginning balance Weighted Avg. Exercise Price, Outstanding, Beginning balance Number of shares, Options granted Weighted Avg. Exercise Price, Options granted Number of shares, Options exercised Weighted Avg. Exercise Price, Options exercised Number of shares, Options cancelled/forfeited Weighted Avg. Exercise Price, Options cancelled/forfeited Number of shares, Outstanding, Ending balance Weighted Avg. Exercise Price, Outstanding, Ending balance Weighted Avg. Remaining Contractual Life, Options outstanding Aggregate Intrinsic Value, Options outstanding Number of shares, Options exercisable Weighted Avg. Exercise Price, Exercisable Ending Balance Weighted Avg. Remaining Contractual Life, Options exercisable Aggregate Intrinsic Value, Options exercisable Number of shares, Options vested and expected to vest Weighted Avg. Exercise Price, Vested and expected to vest Weighted Avg. Remaining Contractual Life, Options vested and expected to vest Aggregate Intrinsic Value, Options vested and expected to vest Weighted-average fair value of options granted Expected terms (in years) Expected volatility Risk-free interest rate, minimum Risk-free interest rate, maximum Dividend yield Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of Exercise Prices, minimum Range of Exercise Prices, maximum Number of Options Outstanding Weighted Average Remaining Contractual Life in Years Weighted Average Exercise Price Number Exercisable Weighted Average Exercisable Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Number of RSUs unvested, Outstanding, Beginning balance Weighted Average Grant Date Fair Value, Beginning balance Number of RSUs granted Weighted Average Grant Date Fair Value, RSUs granted Number of RSUs vested Weighted Average Grant Date Fair Value, RSUs vested Number of RSUs cancelled/forfeited Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited Number of RSUs unvested, Outstanding, Ending balance Weighted Average Grant Date Fair Value, Ending balance Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Number of Shares Warrants Outstanding, beginning balance Weighted Avg. Exercise Price, Outstanding, beginning balance Number of Shares Warrants Outstanding, Granted Number of Shares Warrants Outstanding, Exercised Weighted Avg. Exercise Price, Granted Number of Shares Warrants Outstanding, Expired Number of Shares Warrants Outstanding and Exercisable, ending balance Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance Weighted average remaining contractual life of the outstanding warrants in years Warrants issuance date Warrants Outstanding Exercise Price Expiration Date Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items] Stock-based Compensation Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Sale of Stock, Number of Shares Issued in Transaction Preferred Stock, Liquidation Preference Per Share Payments of Stock Issuance Costs Preferred Stock, Voting Rights Preferred Stock, Dividend Rate, Percentage Accrued and unpaid dividends Preferred stock, cash dividends Number of shares isssued Number of securities called by warrants Warrants exercise price Net proceeds received Shares issued of restricted common stock, shares Number of stock withheld for payroll tax purposes Value of stock withheld for payroll tax purposes Maximum number of common stock issuance under the plan Shares available for future issuances Closing price of common stock price per share Share-based compensation, contractual term Share-based compensation, description Unrecognized compensation expense related to unvested stock options granted under the plan Weighted-average period for recognition Intrinsic value of options exercised Number of restrcited shares, value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Stock option contractual term Derivative, Variable Interest Rate Loss Contingencies [Table] Loss Contingencies [Line Items] Litigation settlement agreement, description Estimated one-time payment Estimated litigation settlement expense Royalty payment description Royalty expense Sales revenue net Accounts payable Accounts payable Commission payments percentage Commission expense incurred Product acquisition description Shares returned Shares reacquired Royalty payments [custom:CommercialPaymentsForRoyalties] Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Gross profit Segment contribution Operating income (loss) Amortization Schedule of Revenue by Major Customers, by Reporting Segments [Table] Revenue, Major Customer [Line Items] Number of operating segments, description. Concentration risk percentage Common stock 0.001 par value per share [Member] Investment one. Gain loss on forgiveness of debt. Product sales net [Member] Other revenues [Member] Equity in losses of unconsolidated entities. Investment (loss) gain from net Preferred dividends and accretion of preferred stock issuance costs. Total harrow health inc stockholders equity [Member] Sale of stock, net of costs (ATM). Stock issued during period shares shares restricted stock award gross. Stock issued during period for exercise of warrants. Issuance of preferred shares. Stock issued during period shares for exercise of warrants. Stock issued of preferred shares during period. Amortization of intangible asset. Amortization of operating lease rightofuse assets. Proceeds from sale of preferred stock net of discount and issuance costs. Reconciliation of cash cash equivalents and restriced cash at end of period abstract. Reconciliation of cash and cash equivalents. Reconciliation restricted cash. Cash cash equivalents and restricted cash at end of period. Right of use asset obtained in exchange for lease obligation. Gain Loss On Investments One. Net proceeds from paycheck protection loan. Payment of taxes for vesting of restricted stock unit. Repayment of preferred stock. Accounts receivable transferred to note receivable. Stock issued during period value restricted stock. Interest income paid in kind from note receivable. Stock issued during period value for exercise of warrants. Proceeds from payments for stock options exercised. Stock issued during period value employee benefit plans. Risks Uncertainties And Liquidity Policy [Text Block]. Noncontrolling Interest Policy [Text Block]. Investment One Policy [Text Block]. Investment Two Policy [Text Block]. Impairment of Equity Method Investments and Note Receivable Policy [Text Block]. Research and Development Policy [Text Block]. Reclassifications Policy [Text Block]. Investments And Agreements Related Party Transactions [Text Block]. Restricted Cash [Text Block]. Condensed Income Statement One [Table Text Block]. Condensed Balance Sheet One [Table Text Block]. Prepaid Expenses And Other Curren tAssets [Table Text Block]. Schedule of Warrants Outstanding and Exercisable [Table Text Block] Diluted Common Equivalent Shares [Table Text Block]. Diluted Net Income Per Share [Table Text Block]. Consolidation basis, description. Unvested restricted stock units. Vested restricted stock units. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Eton Pharmaceuticals, Inc. [Member] Melt Pharmaceuticals, Inc. [Member] Surface Pharmaceuticals Inc [Member] Commissions Member. Management Services Agreement [Member] Mel Loan Agreement Member. Prepaid Expense And Other Assets Current. Licenses [Member] Non-Competition Clause [Member] State Pharmacy Licenses [Member] Finite Lived Intangible Assets Impairment. Term Loan and Security Agreement [Member] SWK Funding LLC [Member] Debt instrument additional principal amount. Debt Issuance Expenses. Business Loan Agreement [Member] Notes Payable Current. Long-Term Notes Payable. San Diego [Member] Lease expiration date description. Ledgewood [Member] Additional Square Footage of Lease [Member] Nashville [Member] Weighted average incremental borrowing rate, operating lease. FinancingLease Weighted Average Incremental Borrowing Rate. Series B Cumulative Preferred Stock Redeemed [Member] Mark L. Baum [Member] Andrew R. Boll [Member] 2017 Incentive Stock and Awards Plan [Member] Closing price of common stock price per share. Stock Option Plan [Member] Employees and Consultant [Member] Employees [Member] Stock Option Plan [Member] Options Granted to Employees [Member] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price. Weighted Average Exercise Price Granted. Number of shares warrants outstanding and exercisable, ending balance. Share based compensation arrangement by share based payment award non options equity instruments outstanding and exercisable weighted average exercise price. Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term. Warrants issuance date. Lender Warrants [Member] Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format. Selling, General and Administrative [Member] Employees Research and Development [Member] Consultants Selling General and Administrative [Member] Initial Payment [Member] Richard L. Lindstrom, M.D [Member] License Agreement [Member] Second Payment [Member] Final Payment [Member] Net sales of product. Klarity License Agreement [Member] Royalty payment description. Injectable Asset Purchase Agreement [Member] Product acquisition description. Asset Purchase License And Related Agreements [Member] Shares Returned. Mayfield Pharmaceuticals [Member] Shares Reacquired. Asset Purchase Agreement [Member] Stowe License Agreement [Member] Sintetica Agreement [Member] Due Within 30 Days [Member] Sales and Marketing Agreements [Member] Commission payments, percentage. ImprimisRx [Member] Segment contribution. Pharmaceutical Drug Development [Member] Asset Sales And Impairments Net [Member] Number of operating segments, description. Two Product Concentration Risk [Member] Three Main Suppliers [Member] Net reduction in right-of-use assets and lease obligations due to modifications. Stock Option Plan [Member] [Default Label] Assets, Current Liabilities, Current Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Cost of Goods and Services Sold Operating Expenses Interest Expense Nonoperating Income (Expense) Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Attributable to Parent Preferred Stock Dividends and Other Adjustments Shares, Outstanding Stock Redeemed or Called During Period, Shares Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings GainLossOnInvestmentsOne InterestIncomePaidinkindFromNoteReceivable Gain (Loss) on Disposition of Assets Gain (Loss) on Extinguishment of Debt Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Employee Related Liabilities Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Notes Receivable Payments to Acquire Intangible Assets Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Repayments of Notes Payable PaymentOfTaxesForVestingOfRestrictedStockUnit RepaymentOfPreferredStock Payments of Ordinary Dividends, Preferred Stock and Preference Stock Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations ReconciliationRestrictedCash Commitments and Contingencies Disclosure [Text Block] Condensed Income Statement [Table Text Block] AccountsReceivableTransferredToNoteReceivable Total prepaid expenses and other current assets Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Amortization of Intangible Assets Finite-Lived Intangible Assets, Net Accounts Payable and Accrued Liabilities Long-Term Debt, Maturity, Remainder of Fiscal Year Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Long-term Debt Interest Payable, Current Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Five Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year Two Finance Lease, Liability, to be Paid, Year Three Finance Lease, Liability, Payment, Due Finance Lease, Liability, Undiscounted Excess Amount Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Weighted Avg. Exercise Price, Outstanding, beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Number of Shares Warrants Outstanding and Exercisable, ending balance Warrant AccountsPayableToRelatedParty Accounts Payable, Current